Last updated: September 14, 2026
Tafamidis meglumine, marketed by Pfizer as Vyndaqel, is a leading treatment for transthyretin amyloidosis. Its commercial position expanded sharply after U.S. approval for transthyretin amyloid cardiomyopathy in 2019. Pfizer reported approximately $6.4 billion in 2024 worldwide revenue for the Vyndaqel family, compared with about $3.3 billion in 2023 and $2.4 billion in 2022.[1] The franchise remains one of Pfizer’s most important growth products, but its long-term outlook depends on patent protection, generic entry, competition from acoramidis and RNA-based therapies, and broader diagnosis of ATTR cardiomyopathy.
What is tafamidis meglumine and how is it marketed?
Tafamidis meglumine is the meglumine salt of tafamidis, a transthyretin stabilizer. It binds to thyroxine-binding sites on the transthyretin tetramer and reduces tetramer dissociation, a process associated with amyloid fibril formation.[2]
Pfizer commercializes two U.S. tafamidis products:
| Product |
Active form |
U.S. indication |
FDA approval |
| Vyndaqel |
Tafamidis meglumine |
Wild-type or hereditary ATTR cardiomyopathy |
2019 |
| Vyndamax |
Tafamidis free acid |
Wild-type or hereditary ATTR cardiomyopathy |
2019 |
| Vyndaqel |
Tafamidis meglumine |
Hereditary ATTR polyneuropathy |
2011 approval outside the U.S.; U.S. cardiomyopathy approval in 2019 |
Vyndaqel contains four 20-mg tafamidis equivalents per daily dose. Vyndamax is a once-daily 61-mg capsule containing tafamidis free acid. The products are not interchangeable on a milligram-for-milligram basis, although both provide an equivalent daily tafamidis dose for cardiomyopathy.[3]
Pfizer’s commercial strategy has favored Vyndamax in the United States because its single-capsule dosing is simpler than the four-capsule Vyndaqel regimen.
How large is the tafamidis meglumine market?
The global tafamidis market is concentrated in Pfizer’s Vyndaqel franchise. Pfizer reported the following worldwide revenue:
| Fiscal year |
Vyndaqel family revenue |
Year-over-year change |
| 2022 |
Approximately $2.4 billion |
Approximately 29% |
| 2023 |
Approximately $3.3 billion |
Approximately 40% |
| 2024 |
Approximately $6.4 billion |
Approximately 94% |
The 2024 increase reflected stronger demand in the United States and international markets, improved diagnosis of ATTR cardiomyopathy, higher treatment penetration, and favorable foreign-exchange effects in some periods.[1]
The apparent acceleration from 2023 to 2024 should be interpreted carefully. Pfizer’s reporting and product-family presentation can affect period-to-period comparisons, and the Vyndaqel family includes both tafamidis meglumine and tafamidis free acid products. Even with that qualification, the franchise has moved from a specialty orphan product to a multibillion-dollar global cardiovascular asset.
What drives demand for tafamidis?
Demand is primarily determined by four factors:
- More patients are being diagnosed with wild-type ATTR cardiomyopathy.
- Cardiac imaging, genetic testing and nuclear scintigraphy are improving case identification.
- Patients are receiving treatment earlier in the disease course.
- Physicians are adopting tafamidis as the established disease-modifying therapy for ATTR cardiomyopathy.
The diagnosed population remains smaller than the likely prevalence of ATTR disease. This creates room for continued volume growth, although the rate of expansion should moderate as major cardiology centers reach higher treatment penetration.
What is the financial trajectory for Vyndaqel and Vyndamax?
Pfizer’s Vyndaqel franchise has become a major offset to declining revenue from older products and selected COVID-19 products. The product’s revenue trajectory has been unusually strong because it combines orphan-disease pricing with expansion into a larger cardiomyopathy population.
Revenue outlook
A reasonable commercial framework is:
| Period |
Primary growth driver |
Main constraint |
| 2024-2026 |
Diagnosis growth and international penetration |
High price and reimbursement controls |
| 2026-2028 |
Continued treatment adoption and earlier diagnosis |
Acoramidis competition and patent challenges |
| After major patent expiry |
Residual brand demand and geographic differences |
Generic tafamidis and price erosion |
Pfizer has not disclosed a single public global revenue forecast that establishes a definitive peak-sales figure for the franchise. External market estimates have generally placed peak sales in the high-single-digit billions, but estimates vary based on diagnosis rates, pricing, treatment duration and the timing of generic competition.
The principal financial risk is concentration. A large share of the franchise’s future value depends on one therapeutic mechanism and one disease category. A competing transthyretin stabilizer with similar efficacy, a lower price or better dosing could pressure new-patient starts before generic entry.
When does tafamidis lose exclusivity?
Tafamidis has different exclusivity dates depending on the country, product, indication and patent claim. The most important U.S. protection relates to patents covering tafamidis composition, formulations, treatment methods and cardiomyopathy use.
The FDA approved tafamidis for ATTR cardiomyopathy in 2019. The approval received orphan-drug exclusivity associated with the cardiomyopathy indication. Orphan exclusivity generally lasts seven years from approval, subject to the specific regulatory scope and statutory exceptions. That period does not eliminate patent protection and does not prevent all forms of competing approval.[3]
The earliest basic compound protection has largely expired or is no longer the primary commercial barrier. The more important U.S. barriers are later patents covering therapeutic use and product-specific protection. Public patent records identify foundational tafamidis patents, including U.S. Patent No. 7,214,388, which covers benzoxazole derivatives associated with transthyretin amyloidosis. Later method-of-use patents have been material to the cardiomyopathy franchise.[4]
Because patent expiration dates can change through patent-term adjustment, pediatric extensions, terminal disclaimers, reexamination and litigation outcomes, the controlling date for a generic launch is the active patent and regulatory record at the time of review. The FDA Orange Book should be used for current listed patents and exclusivity information.[5]
What patents protect tafamidis meglumine?
The tafamidis estate has several protection categories:
| Protection category |
Commercial purpose |
| Active compound patents |
Protect tafamidis and related benzoxazole compounds |
| Salt and pharmaceutical-composition claims |
Protect tafamidis meglumine and drug-product compositions |
| Treatment-method claims |
Cover treatment of ATTR polyneuropathy or cardiomyopathy |
| Dose and administration claims |
Protect specific daily dosing regimens |
| Product and formulation claims |
Protect dosage forms, capsule compositions and manufacturing characteristics |
| Regulatory exclusivity |
Delays certain competing approvals independently of patent expiry |
The strongest remaining claims are likely the ones directed to use in ATTR cardiomyopathy and specific approved dosage regimens, rather than the original compound claims. Method-of-use claims can be commercially significant because an ANDA applicant must address Orange Book-listed patents even when the active ingredient itself is no longer protected.
Patent strength depends on claim scope and enforcement history. A narrow method claim may be vulnerable to a non-infringing label or a section viii carve-out. A broader treatment claim may create greater launch risk but may face validity challenges based on prior clinical knowledge, obviousness or written-description issues.
What is the Orange Book status of Vyndaqel and Vyndamax?
Vyndaqel and Vyndamax are FDA-approved prescription products listed under Pfizer’s tafamidis approvals. Orange Book analysis should distinguish:
- The Vyndaqel NDA for tafamidis meglumine.
- The Vyndamax NDA for tafamidis free acid.
- Patents listed against each NDA.
- Indication-specific exclusivity.
- Any patent certifications filed by ANDA applicants.
- Whether a patent is listed against the salt, the free-acid product or the method of use.
A generic applicant seeking approval of tafamidis meglumine would generally file an ANDA and address listed patents through one or more certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed. Pfizer could then bring an infringement action within 45 days, potentially triggering a 30-month stay of final approval under the Hatch-Waxman framework.[6]
Publicly available information does not establish a broadly launched U.S. generic tafamidis product. The absence of a marketed generic does not prove that no Paragraph IV filing exists, because ANDA filings and some litigation details may remain nonpublic until litigation, FDA action or commercial launch.
Which companies are challenging tafamidis exclusivity?
Potential challengers include generic manufacturers with experience in complex oral products and companies seeking to enter the ATTR market through alternative mechanisms. A challenger may pursue:
- A generic tafamidis meglumine capsule.
- A generic tafamidis free-acid product.
- A patent settlement with a negotiated launch date.
- A competing transthyretin stabilizer rather than a direct generic.
- An RNA-silencing or antisense product that competes clinically without infringing tafamidis patents.
No confirmed, widely reported U.S. commercial launch by a tafamidis generic manufacturer has established a new market structure as of the latest publicly available Pfizer reporting period.[1] Competitive pressure is therefore currently more visible from branded alternatives than from generic substitution.
What competitive drugs threaten tafamidis?
Acoramidis
Acoramidis, marketed in the United States as Attruby by BridgeBio Pharma and its affiliates, was approved by the FDA in 2024 for adults with wild-type or hereditary ATTR cardiomyopathy.[7] It is a transthyretin stabilizer and the most direct branded competitor to tafamidis.
The commercial comparison is significant:
| Factor |
Tafamidis |
Acoramidis |
| Mechanism |
Transthyretin stabilization |
Transthyretin stabilization |
| U.S. cardiomyopathy approval |
2019 |
2024 |
| Originator |
Pfizer |
BridgeBio |
| Competitive issue |
Established standard and broad physician familiarity |
New clinical and pricing alternative |
| Generic risk |
Relevant after patent barriers weaken |
Not yet the primary issue |
Acoramidis can pressure Pfizer through formulary negotiations, new-patient switching and price comparisons. It may have a larger effect on future growth than on the existing treated base, because established patients may be reluctant to change a tolerated therapy.
RNA-based therapies
Patisiran, vutrisiran and eplontersen reduce transthyretin production rather than stabilizing the circulating tetramer. These products may compete in patients with mixed cardiac and neurologic disease or in patients for whom physicians prefer gene-silencing approaches.[8]
Their administration schedules differ from oral tafamidis. That creates both competitive risk and market segmentation. Oral daily treatment is convenient for many patients, while periodic injection or infusion may be attractive when adherence, disease severity or combined organ involvement is a concern.
What generic launch risks exist for tafamidis?
The generic launch risk is moderate in the near term and potentially high over the longer term.
Near-term barriers
- Product-specific patents may remain enforceable.
- A generic sponsor must demonstrate pharmaceutical equivalence and bioequivalence.
- Tafamidis has separate salt and free-acid products.
- A generic applicant must address method-of-use patents.
- Orphan exclusivity and patent litigation can delay approval.
- Small patient populations can make generic development less attractive.
Longer-term risks
Once a legally permissible generic launches, price erosion could be substantial. The magnitude will depend on the number of approved suppliers, the timing of launches, payer substitution rules and whether generic tafamidis meglumine is considered interchangeable with Vyndamax. Pfizer could retain some patients through brand loyalty, supply reliability and contracting, but the highest-volume product would likely face reimbursement pressure.
A first generic entrant could obtain a period of commercial advantage without necessarily receiving a full statutory exclusivity period, depending on the ANDA and Paragraph IV history. Settlement agreements could also create an authorized generic or a delayed entry date.
How strong is the tafamidis patent estate?
The estate is commercially meaningful but less durable than a newly launched small-molecule franchise. Its strengths are:
- Multiple product presentations.
- Approved cardiomyopathy use.
- Method-of-use claims tied to a defined disease.
- High product value per treated patient.
- Regulatory and clinical differentiation from non-stabilizer therapies.
Its weaknesses are:
- Foundational compound protection is old.
- The active ingredient is a small molecule with a clear chemical identity.
- Method-of-use claims may be vulnerable to invalidity or carve-out strategies.
- Competing therapies can reduce the value of future patient additions before generic entry.
- The product has no biologic manufacturing barrier.
The estate’s effective life therefore depends less on the original compound patent and more on the enforceability of later cardiomyopathy and formulation claims.
What manufacturing and intellectual-property barriers affect entry?
Tafamidis is an oral small molecule, so it does not have the manufacturing complexity of a biologic. A generic manufacturer still must control:
- Chemical synthesis and impurity profiles.
- Salt formation or free-acid conversion.
- Particle size and dissolution characteristics.
- Capsule filling and content uniformity.
- Stability and packaging.
- Bioequivalence across the relevant product form.
These requirements create development costs but are unlikely to create a permanent barrier comparable to an antibody or RNA therapeutic manufacturing platform. The principal entry barrier is legal and regulatory, not production capacity.
What litigation and settlement issues affect tafamidis?
The key litigation question is whether Pfizer sues an ANDA filer within the 45-day period after receiving a Paragraph IV notice. If it does, FDA approval may be stayed for up to 30 months unless the litigation ends earlier or a court modifies the stay.[6]
A settlement could specify:
- A permitted generic entry date.
- A license to manufacture or sell.
- A supply arrangement.
- An authorized-generic commitment.
- Restrictions on launch before particular patent expirations.
- Allocation of litigation risk between Pfizer and the generic sponsor.
No publicly established settlement has reset the U.S. market into a confirmed generic-entry timetable in the available Pfizer and FDA materials reviewed for this analysis.[1,5]
How does tafamidis compare with acoramidis and RNA therapies?
Tafamidis has the strongest commercial position because it entered the market earlier, has established reimbursement and has accumulated substantial physician experience. Acoramidis has the clearest direct competitive rationale. RNA therapies may capture patients with more complex disease or a preference for transthyretin reduction.
| Attribute |
Tafamidis |
Acoramidis |
RNA therapies |
| Product type |
Oral stabilizer |
Oral stabilizer |
Injectable or infusion-based |
| Market maturity |
Established |
Newly launched |
Established in selected indications |
| Main advantage |
Clinical familiarity and treatment scale |
Direct stabilizer competition |
TTR reduction and potential neurologic utility |
| Main risk to Pfizer |
Generic entry and branded price competition |
New-patient share loss |
Segmentation of high-risk patients |
| Manufacturing barrier |
Low to moderate |
Low to moderate |
Higher |
What is the investment outlook for tafamidis?
Tafamidis remains a high-value Pfizer franchise with strong near-term cash-generation potential. Revenue growth should continue while diagnosis and treatment penetration expand. The principal valuation variables are:
- The number of diagnosed ATTR cardiomyopathy patients.
- Annual net price after rebates and government discounts.
- Acoramidis uptake.
- The timing of generic litigation and settlements.
- Patent validity and enforceability.
- Pfizer’s ability to maintain Vyndaqel and Vyndamax reimbursement.
- Treatment duration and patient persistence.
The franchise has a favorable near-term profile but a more exposed long-term profile. A multibillion-dollar product with an aging small-molecule patent base can experience rapid value loss after the first credible generic launch, particularly if multiple suppliers enter simultaneously.
Key Takeaways
- Tafamidis meglumine is marketed mainly through Pfizer’s Vyndaqel franchise, alongside Vyndamax tafamidis free acid.
- Pfizer reported approximately $6.4 billion in Vyndaqel-family revenue in 2024.
- Growth has been driven by ATTR cardiomyopathy diagnosis, treatment penetration and international expansion.
- Acoramidis is the most direct branded competitor after its 2024 U.S. approval.
- RNA-based therapies compete through transthyretin reduction and different administration models.
- The original tafamidis compound protection is less important than later cardiomyopathy, formulation and method-of-use patents.
- U.S. generic risk depends on Orange Book listings, Paragraph IV certifications, litigation and settlement terms.
- Tafamidis has low biologic-style manufacturing barriers, making patent and regulatory protection more important than production complexity.
- The near-term outlook remains strong, while long-term value depends on the timing and structure of generic entry.
FAQs
Is tafamidis meglumine the same as Vyndaqel?
Yes. Vyndaqel contains tafamidis meglumine. Vyndamax contains tafamidis free acid and uses a different capsule strength to deliver an equivalent daily tafamidis dose.
Is tafamidis a biologic drug?
No. Tafamidis is a chemically synthesized small-molecule drug. It does not face biosimilar competition under the Biologics Price Competition and Innovation Act.
Can generic manufacturers substitute tafamidis meglumine for Vyndamax?
Not automatically. Vyndaqel and Vyndamax contain different chemical forms and have separate product approvals. Substitution depends on FDA approval, pharmacy rules, product labeling and any applicable equivalence determination.
What disease has created most of tafamidis revenue growth?
ATTR cardiomyopathy has driven the major commercial expansion. The U.S. approval for wild-type or hereditary ATTR cardiomyopathy in 2019 opened a larger market than the earlier hereditary ATTR polyneuropathy opportunity.
Does acoramidis have a biosimilar relationship to tafamidis?
No. Acoramidis is a separate small-molecule drug and a branded competitor. It is not a biosimilar and does not rely on tafamidis clinical or manufacturing data through a biosimilar pathway.
References
- Pfizer Inc. (2025). 2024 annual report. Pfizer Investor Relations.
- U.S. Food and Drug Administration. (2019). Vyndaqel and Vyndamax prescribing information.
- U.S. Food and Drug Administration. (2019). FDA approves new treatments for heart disease caused by transthyretin-mediated amyloidosis.
- U.S. Patent and Trademark Office. (2007). U.S. Patent No. 7,214,388: Benzoxazole derivatives for the treatment of diseases associated with transthyretin.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2024). Patent certification and 30-month stay provisions under the Hatch-Waxman Act.
- U.S. Food and Drug Administration. (2024). FDA approves acoramidis for cardiomyopathy caused by transthyretin-mediated amyloidosis.
- European Medicines Agency. (2024). Medicines for transthyretin amyloidosis: tafamidis, patisiran, vutrisiran and eplontersen product information.
